[{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","commit":"9cbd69eefa","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fourth batch of thirty approved products","file":"src/data/spikes/cll.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Obinutuzumab\" }]"}]},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/cll.ts","type":"changed","fields":[{"field":"tldr","before":"\"A supercharged CD20 antibody that, paired with venetoclax for one year, gives many CLL patients years off all treatment.\"","after":"\"Obinutuzumab is a supercharged CD20 antibody that, paired with venetoclax for one year, gives many CLL patients years off all treatment.\""}]},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","commit":"713bfbdd72","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: AML, ALL, CLL deep dives (102 new entities: trials with structured outcomes, products with dosing/toxicity/regulatory events, target","file":"src/data/spikes/cll.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"},{"field":"terms"}]}]